Temozolomide and Radiotherapy vs Radiotherapy Alone in IDH-Wildtype Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial
Clin. Cancer Res 2022 Mar 11;[EPub Ahead of Print], CMS Tesileanu, M Sanson, W Wick, AA Brandes, PM Clement, SC Erridge, MA Vogelbaum, AK Nowak, JF Baurain, WP Mason, H Wheeler, OL Chinot, S Gill, M Griffin, L Rogers, W Taal, R Rudà, M Weller, C McBain, ME van Linde, K Aldape, RB Jenkins, JM Kros, P Wesseling, A von Deimling, Y Hoogstrate, I de Heer, PN Atmodimedjo, HJJ Dubbink, RWW Brouwer, WFJ van IJcken, KJ Cheung, V Golfinopoulos, BG Baumert, T Gorlia, PJ French, MJ van den BentFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.